2nd Annual Genomics Meeting: Genomics and Translational Medicine in Myeloma

July 12 - 13, 2024 - Hilton Barcelona, Barcelona, Spain

The IMS Genomics Meeting was developed in response to the IMS-FDA joint workshop to further consider essential needs in myeloma. The initial invitation-only meeting in 2023 provided an opportunity for myeloma experts from around the world to develop a consensus to define ‘high-risk multiple myeloma’. Building upon this success, the Second IMS Genomics Meeting will be a public meeting led by global myeloma KOL.

In addition to which, this day and a half-long meeting will include sessions on:

  • Risk Stratification validation
  • Genomically targeted therapies
  • New technologies
  • Genomic Biomarkers for stratification of clinical studies
  • New clinical trials for patients with HR disease
Our sponsors:

Tentative Agenda 

In Person Registration

  • Admission to scientific sessions.
  • Admission to breakfasts, lunches, and coffee breaks.
  • Certificate of attendance.
  • One-year access to on-demand session recordings. Access instructions will be provided 3 weeks post-event.


On-demand Registration

  • One-year access to on-demand session recordings. Access instructions will be provided within 3 weeks post-event.


Why Become a Member

The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.

The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.

Stay updated on our Events